Join our measuringhero Jay on the innovation tour

Experience our latest innovation from the Control fair.

Quretech granted a European patent for a new type of antibiotic

The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

First preterm infants study – a vital step for Neola

After years of developing an advanced lung monitoring system, Neola Medical has received some delightful news: permission to start its first clinical study on p...

Björn Arvidsson will lead research and innovation in Region Uppsala

The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.

Topp 50: Här är Sveriges högst rankade medicinforskare

Kaj Blennow, Tomas Hökfelt och Anders Björklund toppar listan över de svenska forskare som citeras mest frekvent inom det medicinska forskningsfältet. Se de 50 ...

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

Explore our tailored program for Control 2025

Choose an innovation tour, or join our industry-specific guided tours.

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Achieve Effortless, Standardized Automation with the new ZEISS Automation Interface

Simple interfaces for automated loading of CMMs.

Career coach on salaries: “There is no right or wrong”

What is a reasonable salary for my job? It's a question we all ask ourselves. But how important is a higher salary really? Career coach Tina Persson believes th...

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool

Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals...

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...

The business coach: “We need to learn from our mistakes”

The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Improving Nano-Structured Surfaces for Implants with Scanning Electron Microscopy

Promimic, a Swedish company specializing in the development and marketing of nano-structured surfaces for implants, heavily relies on scanning electron microscopes.

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.